Recent Updates
Recently added Catalysts
STRO

AACR Annual Meeting 2026 – Presentation and Posters

Key Takeaway: At the AACR Annual Meeting 2026, Sutro Biopharma presented several promising findings related to their investigational therapies. Notably, STRO-004 demonstrated superior efficacy in treating TF-expressing solid tumors. Additionally, a Phase 1 study highlighted its safety and preliminary anti-tumor activity. Other presentations included advancements in dual-payload antibody-drug conjugates targeting various cancer mechanisms.
Price reaction · baseline $35.045 (2026-04-21T14:28:00.000Z) · hit during market hours · clean, no other STRO news in the window
day 0 close · peak
-2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~13 mo
Low dilution risk
Lead asset
STRO-004
Phase 1 · Head and Neck Squamous Cell Carcinoma HNSCC

Full Press Release Details

[et_pb_section fb_built=”1″ _builder_version=”4.16″ custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_post_title author=”off” categories=”off” comments=”off” admin_label=”15th Annual World ADC Conference – Presentation” _builder_version=”4.23.4″ title_level=”h2″ title_text_color=”#0c71c3″ title_font_size=”28px” title_letter_spacing=”1px” title_line_height=”1.4em” meta_text_color=”#000000″ global_colors_info=”{}”][/et_pb_post_title][et_pb_divider color=”#0badbc” divider_weight=”2px” _builder_version=”4.16″ global_colors_info=”{}”][/et_pb_divider][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”19px” global_colors_info=”{}”]
STRO-004, a Next-Generation Tissue Factor (TF)-Targeted DAR8-Exatecan ADC, Demonstrates Superior Efficacy Across TF-Expressing Solid Tumors in a Comprehensive Single-Mouse PDX Trial
Presenter: Genevive Hernandez, Ph.D.
[/et_pb_text][et_pb_button button_url=”https://www.sutrobio.com/wp-content/uploads/2026/04/STRO-004_AACR2026_GH_19apr2026.pdf” url_new_window=”on” button_text=”Presentation” button_alignment=”left” admin_label=”Presentation – Button” _builder_version=”4.27.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#0C71C3″ button_bg_color=”#FFFFFF” button_border_width=”1px” button_border_color=”#0C71C3″ button_border_radius=”3px” button_icon=”||divi||400″ button_icon_color=”#0C71C3″ button_on_hover=”off” global_colors_info=”{}”][/et_pb_button][et_pb_gallery gallery_ids=”17826,17827,17828,17829,17830,17831,17832,17833,17834,17835,17836,17837,17838,17839,17840,17841,17842,17843,17844,17845″ fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” pagination_text_color=”#FFFFFF” module_alignment=”center” global_colors_info=”{}”][/et_pb_gallery][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”19px” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]
Phase 1 open-label study to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity of STRO-004 in adults with refractory/recurrent metastatic solid tumors
Presenter: Jennifer Oliver, MD
[/et_pb_text][et_pb_button button_url=”https://www.sutrobio.com/wp-content/uploads/2026/04/Sutro_AACR-2026_-STRO-004-STI-TiP-V4_Final.pdf” url_new_window=”on” button_text=”Presentation” button_alignment=”left” admin_label=”Presentation – Button” _builder_version=”4.27.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#0C71C3″ button_bg_color=”#FFFFFF” button_border_width=”1px” button_border_color=”#0C71C3″ button_border_radius=”3px” button_icon=”||divi||400″ button_icon_color=”#0C71C3″ button_on_hover=”off” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_button][et_pb_gallery gallery_ids=”17853″ fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” pagination_text_color=”#FFFFFF” module_alignment=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_gallery][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”19px” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]
STRO-006: An Integrin beta-6–targeting ADC demonstrates favorable safety profile and potent antitumor activity in preclinical solid tumors
Presenter: Kshama Doshi, Ph.D.
[/et_pb_text][et_pb_button button_url=”https://www.sutrobio.com/wp-content/uploads/2026/04/AACR-2026_STRO-006-Poster_Final.pdf” url_new_window=”on” button_text=”Presentation” button_alignment=”left” admin_label=”Presentation – Button” _builder_version=”4.27.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#0C71C3″ button_bg_color=”#FFFFFF” button_border_width=”1px” button_border_color=”#0C71C3″ button_border_radius=”3px” button_icon=”||divi||400″ button_icon_color=”#0C71C3″ button_on_hover=”off” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_button][et_pb_gallery gallery_ids=”17858″ fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” pagination_text_color=”#FFFFFF” module_alignment=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_gallery][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”19px” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]
Preclinical characterization of STRO-227: A PTK7-targeting dual-payload ADC with topoisomerase 1 and tubulin inhibitors
Presenter: Daniel Calarese, Ph.D.
[/et_pb_text][et_pb_button button_url=”https://www.sutrobio.com/wp-content/uploads/2026/04/2025-AACR-STRO-227-Poster-Final-54×31.5-1.pdf” url_new_window=”on” button_text=”Presentation” button_alignment=”left” admin_label=”Presentation – Button” _builder_version=”4.27.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#0C71C3″ button_bg_color=”#FFFFFF” button_border_width=”1px” button_border_color=”#0C71C3″ button_border_radius=”3px” button_icon=”||divi||400″ button_icon_color=”#0C71C3″ button_on_hover=”off” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_button][et_pb_gallery gallery_ids=”17859″ fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” pagination_text_color=”#FFFFFF” module_alignment=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_gallery][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”19px” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]
The HER2-targeting dual-payload antibody-drug conjugate combining a topoisomerase I inhibitor and a microtubule inhibitor demonstrates superior efficacy and overcomes resistance to single-payload ADCs in xenograft models
Presenter: Angela Matcham, Ph.D.
[/et_pb_text][et_pb_button button_url=”https://www.sutrobio.com/wp-content/uploads/2026/04/Matcham_AACRPoster1685_aHER2dpADC_Final.pdf” url_new_window=”on” button_text=”Presentation” button_alignment=”left” admin_label=”Presentation – Button” _builder_version=”4.27.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#0C71C3″ button_bg_color=”#FFFFFF” button_border_width=”1px” button_border_color=”#0C71C3″ button_border_radius=”3px” button_icon=”||divi||400″ button_icon_color=”#0C71C3″ button_on_hover=”off” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_button][et_pb_gallery gallery_ids=”17857″ fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” pagination_text_color=”#FFFFFF” module_alignment=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_gallery][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”19px” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]
Sutro’s Site-Specific Dual-Payload ADCs Combining TOPO1i and DNA Damage Response Inhibitors to Enhance Efficacy, Overcome Resistance, and Improve Safety
Presenter: Krishna Bajjuri, Ph.D.
[/et_pb_text][et_pb_button button_url=”https://www.sutrobio.com/wp-content/uploads/2026/04/Sutro-AACR26-TOPO1i-x-DDRi-dpADC-final-poster-040226.pdf” url_new_window=”on” button_text=”Presentation” button_alignment=”left” admin_label=”Presentation – Button” _builder_version=”4.27.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#0C71C3″ button_bg_color=”#FFFFFF” button_border_width=”1px” button_border_color=”#0C71C3″ button_border_radius=”3px” button_icon=”||divi||400″ button_icon_color=”#0C71C3″ button_on_hover=”off” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_button][et_pb_gallery gallery_ids=”17854″ fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” pagination_text_color=”#FFFFFF” module_alignment=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_gallery][/et_pb_column][/et_pb_row][/et_pb_section]

Frequently Asked Questions

What is STRO-004?

STRO-004 is a next-generation tissue factor-targeted ADC showing efficacy in solid tumors.

Who presented at the AACR Annual Meeting 2026?

Presenters included Genevive Hernandez, Ph.D., and Jennifer Oliver, MD, among others.

What was the focus of the Phase 1 study?

The Phase 1 study evaluated the safety and anti-tumor activity of STRO-004.

What advancements were discussed regarding ADCs?

The presentations highlighted dual-payload ADCs that enhance efficacy and overcome resistance.

Last updated: Apr 21, 2026